REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Melanoma|Merkel Cell Carcinoma|Triple Negative Breast Cancer|Head and Neck Squamous Cell Carcinoma|Renal Cell Carcinoma|Colorectal Cancer|Sarcoma
Interventions: DRUG: NKTR-262|DRUG: bempegaldesleukin|DRUG: nivolumab
Sponsor: Nektar Therapeutics